Mathai Mammen, SVP, Research & Early Clin Development at THERAVANCE INC (THRX), sold 4,416 shares at $12.84 ($57K) on 2010-09-01, disclosed to the SEC on 2010-09-02.
Scheduled sale ($57k) by SVP, Research & Early Clin Development under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| Filing → |
| THRX | SELL | 2013-08-01 | $256K | — | Filing → |
| THRX | SELL | 2013-05-02 | $236K | — | Filing → |
| THRX | SELL | 2013-02-22 | $155K | — | Filing → |